Cytori Ready to Seek EU Approval of ATI-0918 as Bioequivalent to Caelyx for Ovarian Cancer
News
Cytori Therapeutics reports that their compound ATI-0918 is equivalent to Janssen’s Caelyx (doxorubicin) — a previously approved liposomal formulation of doxorubicin hydrochloride for the treatment of ovarian cancer. The data stems ... Read more